Mereo BioPharma (MREO) Other Non-Current Liabilities (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Other Non-Current Liabilities of $362000.0 for Q1 2026, down 13.6% year-over-year from $419000.0 in Q1 2025, and down 45.23% quarter-over-quarter from $661000.0 in Q4 2025.
Mereo BioPharma (MREO) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Other Non-Current Liabilities for 10 consecutive years, with $362000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 13.6% year-over-year to $362000.0; the TTM figure through Mar 2026 stood at $362000.0 (down 13.6% YoY), while the FY2025 annual figure was $661000.0, down 19.49% from the prior year.
- Other Non-Current Liabilities declined to $362000.0 in Q1 2026 per MREO's latest filing, from $661000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.0 million in Q2 2022 and bottomed at $362000.0 in Q1 2026.
- Historically, Other Non-Current Liabilities has averaged $1.3 million across 5 years, with a median of $661000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 94.46% — and 2024, when it surged 79.85%.
- Mereo BioPharma's Other Non-Current Liabilities stood at $622824.9 in 2022, then gained by 22.67% to $764000.0 in 2023, then rose by 7.46% to $821000.0 in 2024, then fell by 19.49% to $661000.0 in 2025, then sank by 45.23% to $362000.0 in 2026.
- Business Quant data shows MREO's Other Non-Current Liabilities at $362000.0 in Q1 2026, $661000.0 in Q4 2025, and $652000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 370,000.00 |
| Mar 31, 2026 | 362,000.00 |
| Dec 31, 2025 | 661,000.00 |
| Sep 30, 2025 | 652,000.00 |
| Jun 30, 2025 | 545,000.00 |
| Mar 31, 2025 | 419,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 925,000.00 |
| Mar 31, 2024 | 855,000.00 |
| Dec 31, 2023 | 764,000.00 |
| Jun 30, 2023 | 514,310.26 |
| Dec 31, 2022 | 622,824.94 |
| Jun 30, 2022 | 8.97 Mn |
| Dec 31, 2021 | 11.24 Mn |
| Jun 30, 2021 | 47.54 Mn |
| Dec 31, 2020 | 67.05 Mn |
| Jun 30, 2020 | 44.40 Mn |
| Dec 31, 2019 | 168,429.96 |
| Jun 30, 2019 | 2.48 Mn |